Swedish Exchange Growth Leaders With High Insider Ownership And Earnings Growth Up To 76%

As global markets exhibit mixed responses to economic indicators, Sweden's market remains a point of interest for investors looking at growth companies with high insider ownership. This focus aligns well with current trends where earnings growth and substantial insider stakes are increasingly viewed as markers of potential resilience and alignment of interests in fluctuating economic climates.

Top 10 Growth Companies With High Insider Ownership In Sweden

Name	Insider Ownership	Earnings Growth
CTT Systems (OM:CTT)	16.9%	21.6%
Spago Nanomedical (OM:SPAGO)	16.1%	52.1%
BioArctic (OM:BIOA B)	35.1%	63%
Calliditas Therapeutics (OM:CALTX)	11.6%	49.9%
Sileon (OM:SILEON)	33.3%	109.3%
InCoax Networks (OM:INCOAX)	18.9%	104.9%
KebNi (OM:KEBNI B)	37.8%	90.4%
Egetis Therapeutics (OM:EGTX)	17.6%	98.2%
Yubico (OM:YUBICO)	37.5%	43%
SaveLend Group (OM:YIELD)	24.8%	106.8%

Click here to see the full list of 85 stocks from our Fast Growing Swedish Companies With High Insider Ownership screener.

Here we highlight a subset of our preferred stocks from the screener.

KlaraBo Sverige (OM:KLARA B)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: KlaraBo Sverige AB operates in Sweden, focusing on the acquisition, construction, ownership, and management of residential properties with a market capitalization of SEK 2.69 billion.

Operations: The company generates revenue through the acquisition, construction, ownership, and management of residential properties in Sweden.

Insider Ownership: 15.1%

Earnings Growth Forecast: 76.8% p.a.

KlaraBo Sverige AB, a Swedish growth company with high insider ownership, shows promising signs despite some financial challenges. While the company's revenue is expected to grow at 5.4% per year, outpacing the Swedish market average of 2.1%, its interest payments are poorly covered by earnings. Notably, KlaraBo is forecasted to become profitable within three years with earnings projected to increase significantly at 76.76% annually. Recent actions include a SEK 30 million share repurchase program aimed at optimizing capital structure and supporting acquisitions, reflecting confidence from management in its growth trajectory and financial health.

• Click here to discover the nuances of KlaraBo Sverige with our detailed analytical future growth report.
• According our valuation report, there's an indication that KlaraBo Sverige's share price might be on the expensive side.

Pandox (OM:PNDX B)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Pandox AB is a Swedish hotel property company that specializes in owning, operating, and leasing hotel properties, with a market capitalization of approximately SEK 33.50 billion.

Operations: The company generates its revenue primarily through two segments: own operation, which brought in SEK 3.24 billion, and rental agreements, contributing SEK 3.76 billion.

Insider Ownership: 12.3%

Earnings Growth Forecast: 46.3% p.a.

Pandox AB, a Swedish company with significant insider ownership, recently reported a robust recovery in its Q1 2024 earnings with sales rising to SEK 812 million and net income turning positive at SEK 447 million. Despite this rebound, challenges persist as the dividend coverage remains weak and profit margins have drastically reduced to 1.1% from last year’s 49.2%. The company’s future earnings are expected to grow by a significant margin annually over the next three years, although revenue growth projections remain modest at an annual rate of 2.2%, slightly above the market average.

• Delve into the full analysis future growth report here for a deeper understanding of Pandox.
• Our valuation report unveils the possibility Pandox's shares may be trading at a discount.

RaySearch Laboratories (OM:RAY B)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: RaySearch Laboratories AB, a medical technology company based in Sweden, specializes in developing software solutions for cancer treatment and operates globally with a market capitalization of approximately SEK 5.01 billion.

Operations: The company generates its revenue from the sale of software solutions for cancer treatment across various global regions including the Americas, Europe, Africa, Asia-Pacific, and the Middle East.

Insider Ownership: 24.1%

Earnings Growth Forecast: 29.6% p.a.

RaySearch Laboratories, a Swedish growth company with high insider ownership, recently declared a combined dividend of SEK 2 per share and reported a substantial increase in Q1 earnings to SEK 36.7 million from the previous year. This performance aligns with its significant annual profit growth forecast of 29.6% over the next three years, outpacing the Swedish market's expectations. Additionally, RaySearch announced strategic alliances to enhance radiation therapy quality, indicating progressive operational advancements and commitment to innovation in medical technology.

• Get an in-depth perspective on RaySearch Laboratories' performance by reading our analyst estimates report here.
• Our comprehensive valuation report raises the possibility that RaySearch Laboratories is priced higher than what may be justified by its financials.

Taking Advantage

• Explore the 85 names from our Fast Growing Swedish Companies With High Insider Ownership screener here.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com